Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel P Bercu

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Regulatory Toxicology and Pharmacology : RTP|June 27, 2012
Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trialsJoel P Bercu, David G Dolan
Regulatory Toxicology and Pharmacology : RTP|August 28, 2012
Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substanceJoel P Bercu, Rizwan Sharnez, David G Dolan
International Journal of Toxicology|December 8, 2009
Overview of genotoxic impurities in pharmaceutical developmentJoel P Bercu, Krista L Dobo, Elmar Gocke, et al.
Regulatory Toxicology and Pharmacology : RTP|June 14, 2008
Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substanceJoel P Bercu, Wherly P Hoffman, Cindy Lee, et al.
Regulatory Toxicology and Pharmacology : RTP|May 31, 2015
Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compoundsBrad Stanard, David G Dolan, William Hanneman, et al.
Regulatory Toxicology and Pharmacology : RTP|March 12, 2008
Human health risk assessments for three neuropharmaceutical compounds in surface watersJoel P Bercu, Neil J Parke, Janice M Fiori, et al.
Chemical Research in Toxicology|January 28, 2009
A strategy for the risk assessment of human genotoxic metabolitesKrista L Dobo, R Scott Obach, Debra Luffer-Atlas, et al.
Regulatory Toxicology and Pharmacology : RTP|May 29, 2016
Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs)Joel P Bercu, Eric J Morinello, Claudia Sehner, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|September 28, 2023
Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamineJoel P Bercu, Shaofei Zhang, Zhanna Sobol, et al.
International Journal of Toxicology|February 2, 2021
Deriving Compound-Specific Exposure Limits for Chemicals Used in Pharmaceutical Synthesis: Challenges in Expert Decision-Making Exemplified Through a Case Study-Based WorkshopWilliam C Drewe, Krista L Dobo, Zhanna Sobol, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Regulatory Toxicology and Pharmacology : RTP|June 27, 2012
Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trialsJoel P Bercu, David G Dolan
Regulatory Toxicology and Pharmacology : RTP|August 28, 2012
Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substanceJoel P Bercu, Rizwan Sharnez, David G Dolan
International Journal of Toxicology|December 8, 2009
Overview of genotoxic impurities in pharmaceutical developmentJoel P Bercu, Krista L Dobo, Elmar Gocke, et al.
Regulatory Toxicology and Pharmacology : RTP|June 14, 2008
Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substanceJoel P Bercu, Wherly P Hoffman, Cindy Lee, et al.
Regulatory Toxicology and Pharmacology : RTP|May 31, 2015
Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compoundsBrad Stanard, David G Dolan, William Hanneman, et al.
Regulatory Toxicology and Pharmacology : RTP|March 12, 2008
Human health risk assessments for three neuropharmaceutical compounds in surface watersJoel P Bercu, Neil J Parke, Janice M Fiori, et al.
Chemical Research in Toxicology|January 28, 2009
A strategy for the risk assessment of human genotoxic metabolitesKrista L Dobo, R Scott Obach, Debra Luffer-Atlas, et al.
Regulatory Toxicology and Pharmacology : RTP|May 29, 2016
Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs)Joel P Bercu, Eric J Morinello, Claudia Sehner, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|September 28, 2023
Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamineJoel P Bercu, Shaofei Zhang, Zhanna Sobol, et al.
International Journal of Toxicology|February 2, 2021
Deriving Compound-Specific Exposure Limits for Chemicals Used in Pharmaceutical Synthesis: Challenges in Expert Decision-Making Exemplified Through a Case Study-Based WorkshopWilliam C Drewe, Krista L Dobo, Zhanna Sobol, et al.
Pageof 3